Bayer and Salus Optima Partner on AI-Enabled Healthy Aging Journey

BayerSalus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

With personalized, data-driven recommendations delivered through mobile applications, the partners provide consumers with tips, recommendations, and motivation to help achieve their individual lifestyle goals and empower them on their aging journey.

This collaboration will combine Salus Optima’s consumer application that provides an AI-enabled 360-degree view of the impact of lifestyle choices and related challenges that consumers face in addressing their health and wellness targets whilst leveraging Bayer’s global footprint and its broad consumer health expertise and portfolio.

Patricia Corsi, Chief Marketing & Information Officer of the Consumer Health division of Bayer commented: "There has never been a better time for our business to support consumer self-care. As the global population ages and we enter an era where many born today will live past 100 years old, understanding and taking action on aging, supported by data and science, is an exciting investment from us to our consumers. With the integration of products, platforms, and devices powered by AI, we put self-care front and center for the people we serve with our business."

Rodrigo Jesus, CEO of Salus Optima added: "We are thrilled to be working with an iconic consumer health brand such as Bayer. This allows us to accelerate time to market, expand our reach and help those that will truly benefit from precision health technologies. Our partnership will address two major global trends in consumer health: personalization and selfcare."

As part of Bayer's commitment to advance precision health and drive innovation in healthy aging, the partnership with Salus Optima follows the recent announcement of the company’s alliance with Hurdle, a pioneer in diagnostic testing. Hurdle's saliva-based biological age test will provide insights that will encourage consumers to utilize Salus Optima's digital application to define individual lifestyle goals as part of their healthy aging journey. With the launch of its precision health business unit earlier this year and these two partnerships, Bayer is building a holistic ecosystem to help address consumer needs on their healthy aging journey.

About Salus Optima

Salus Optima is a B2B, AI-enabled personalised health and wellness company affiliated with McLaren F1. It is a global leader in developing digital engagement products that provide holistic nutrition and lifestyle recommendations for healthier life, work and play. Their core technology is built on years of R&D, tackling the real problems people face in their everyday lives. Leveraging their proprietary software capability, blended with best-in-class science and data, they empower, educate and motivate people to take control over their own health and wellbeing.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

Most Popular Now

Digital ECGs at Barts Health: A High-Imp…

Opinion Article by Dr Krishnaraj Sinhji Rathod, consultant in interventional cardiology, Barts Health NHS Trust. Picture the moment. A patient in an ambulance, enroute to hospital with new chest pain. Paramedics...

Study Sheds Light on Hurdles Faced in Tr…

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools...

Using Deep Learning for Precision Cancer…

Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in Nature Communications, the...

Study Used AI Models to Improve Predicti…

Chronic kidney disease (CKD) is a complex condition marked by a gradual decline in kidney function, which can ultimately progress to end-stage renal disease (ESRD). Globally, the prevalence of the...

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...